Jonathan Bayly

Suggest Changes
  • Citations Per Year
Learn More
SUMMARY Distinguishing oral bisphosphonates from other bone-sparing therapies, this retrospective observational study, first, characterized treated osteoporosis patients in the UK, and secondly,(More)
371 screening in women over 65 years, based on cost-effectiveness analysis. In addition, treatment of women with risk factors other than a prior fracture is costeffective after the age of 65 years(More)
RATIONALE, AIMS AND OBJECTIVES Clinical trial data suggest that patients who have received bisphosphonates continue to benefit from them after discontinuation. However, data from real-world clinical(More)
  • 1